SpineGuard: shares soar after FDA green light

(CercleFinance.com) - SpineGuard's share price soared on Tuesday after it received approval from the U.
S. Food and Drug Administration (FDA) to market its new surgical guidance device.

The Franco-American 'medtech' reports that the health authority has approved its 'PsiFGuard' intelligent drilling tool dedicated to the localization of the sacroiliac joint with a view to simplifying the placement of bone implants

Prior to this new application, SpineGuard had already obtained approval in the USA for an indication involving the anterior approach to the spine.

Building on these successes, the company says it intends to continue expanding the scope of its digital technology for real-time surgical guidance without X-rays, which will lead it to pursue its collaboration with Omnia Medical.

This company, founded by engineers in 2014 and based in Morgantown, West Virginia, specializes in the design of orthopedic implants.

Omnia has developed a range of implants for the spine, particularly with regard to posterior fusion of the sacroiliac joint.

Following these announcements, SpineGuard shares soared by over 48% on Tuesday morning on the Paris Bourse, bringing their gains since the start of the year to over 62%.

Copyright (c) 2024 CercleFinance.com. All rights reserved.